Bin Liu

Bin Liu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2024 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
YWYalong Wu
Yalong Wu
XGXinquan Gu
Xinquan Gu
XCXiaoxi Chen
Xiaoxi Chen
YCYongliang Cui
Yongliang Cui
WJWei Jiang
Wei Jiang
BLBin Liu
Bin Liu
The standard treatment for non-muscle invasive bladder cancer (NMIBC) is transurethral resection of bladder tumor (TURBT).

1 October 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
YLYang Li
Yang Li
YZYuhan Zhang
Yuhan Zhang
NFNa Feng
Na Feng
FYFan Yu
Fan Yu
BLBin Liu
Bin Liu
Purpose: Bladder cancer is a common malignancy of the urinary system and the development of noninvasive therapeutic methods is imperative to avoid radical cystectomy, which results in a poor quality of life for patients. Methods: In this study, ultrasmall copper–palladium nanozymes decorated with cysteamine (CPC) nanoparticles (NPs) were synthesized to enhance the efficacy of radiotherapy (RT) in treating bladder cancer. CPC NPs react with intracellular overexpressed H2O2 in the tumor microenvironment to produce large quantities of reactive oxygen species (ROS) and induce tumor cell apoptosis. Furthermore, the CPC nanozymes can generate ample oxygen within tumors by utilizing H2O2, addressing hypoxia conditions, and mitigating radioresistance. Additionally, CPC facilitates the oxidation of glutathione (GSH) into oxidized glutathione disulfide (GSSG), blocking the self-repair mechanisms of tumor cells post-treatment. Simultaneously, CPC enhances the ionization energy deposition effect on tumor cells. Results: The results demonstrate an increased level of ROS and an elevation in oxygen content at the tumor site. Importantly, tumor growth was restrained without apparent systemic toxicity during the combined treatment. Conclusion: In summary, this study highlights the potential of CPC nanozyme-mediated radiotherapy as a promising avenue for the effective treatment of bladder cancer and demonstrates its potential for future clinical applications in the synergistic therapy of bladder cancer.

1 September 2025 in Nano Research
Verified
Journal Article
Open access
PDF file
JHJiansong Han
Jiansong Han
EJErna Jia
Erna Jia
YGYi Gao
Yi Gao
BLBin Liu
Bin Liu
Kelong FanKelong Fan
Kelong Fan
MLMin Luo
Min Luo
Despite advances in radiotherapy (RT), complete tumor eradication remains a clinical challenge, largely due to the insufficient activation of non-apoptotic cell death pathways such as ferroptosis and cuproptosis. To address this, we developed a bimetallic nanozyme, CuFe-MOF-TPP, comprising a CuFe-based metal–organic framework conjugated with triphenylphosphine to enhance RT sensitivity through provoking cuproptosis and ferroptosis. CuFe-MOF-TPP targeted to mitochondria, destroying redox balance by peroxidase-, oxidase-, and glutathione oxidase-like activities. These catalytic functions promoted excessive reactive oxygen species generation and glutathione depletion, leading to oxidative stress in mitochondria. This redox imbalance triggered the generation of ferrous ions, which accelerated lipid peroxidation and subsequently augmented ferroptosis. Concurrently, cuproptosis was promoted through copper ions-mediated aggregation of dihydrolipoamide S-acetyltransferase. Notably, the combination of CuFe-MOF-TPP and RT result in potent tumor suppression via the coordinated delivery of metal ions and spatiotemporally regulated catalytic activity. This strategy offers a promising approach for overcoming radioresistance by synergistically amplifying mitochondrial oxidative stress and activating ferroptosis and cuproptosis, with significant translational potential for clinical cancer therapy.

31 October 2025 in Medicine
Verified
Journal Article
Open access
JZJiaxiang Zhang
Jiaxiang Zhang
BLBin Liu
Bin Liu
JHJiansong Han
Jiansong Han
JHJiansong Han
Jiansong Han
This study investigates the putative causal relationship between insomnia and urinary system diseases utilizing Mendelian randomization (MR) analysis. Instrumental variables were systematically selected based on predefined criteria. Two-sample MR analysis was performed employing the inverse variance weighted method as the primary analytical approach. The causal associations between insomnia and common urological diseases were ascertained through odds ratios and their corresponding P values. Methodological validity was assessed using MR-Egger regression for pleiotropy evaluation, Cochran’s Q test for heterogeneity assessment, and leave-one-out analysis for sensitivity determination. Positive MR findings underwent validation across multiple datasets, accompanied by preliminary investigation of underlying mechanisms. Within the spectrum of urinary system diseases examined, insomnia exhibited a significant causal association exclusively with diabetic nephropathy. The directional causality demonstrated consistency across various methodological approaches and datasets. Analysis of different insomnia datasets yielded 28 and 39 SNPs as instrumental variables, both successfully satisfying horizontal pleiotropy and heterogeneity criteria. Subsequent MR analyses revealed no evidence of a causal relationship between insomnia and diabetes. Two-sample MR analysis demonstrates a significant causal association between insomnia and diabetic nephropathy, while revealing no direct causal relationships with other common urinary system diseases. This causal association appears to operate independently of insomnia’s effects on diabetes.